Axcella Therapeutics: Interim Results from Phase 2b Clinical Trial for AXA1125 in Non-Alcoholic Steatohepatitis (NASH)
|DATE:||September 29, 2022|
|TIME:||8:00 AM EDT|
About The Event
Please join us for a call with Axcella Therapeutics, featuring Dr. Steven A. Harrison, MD (Pinnacle Clinical Research) who will discuss the clinical context of the data for AXA1125, the large unmet medical need in NASH, and the recent developments on the future landscape.
Axcella Therapeutics leadership will present the newest data from their Phase 2b NASH clinical trial with AXA1125, a multi-targeted therapeutic that is designed to address dysregulated pathways related to liver metabolism, inflammation, and fibrosis. The event will provide a comprehensive overview of the data, as well as provide insight into Axcella Therapeutics’ potential impact in the NASH treatment landscape.
A live Q&A session will follow the formal presentations.
September 29, 2022
8:00 AM EDT
8:00 AM EDT - 9:00 PM EDT